Patients No return to the status quo: Why now is the time for value-b... Value-based, person-centred healthcare is the key to system resilience – and now is the time to make it happen.
News Novo turns to Hengrui for another oral obesity drug Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
